Why did ALNEV.PA stock fall so sharply after-hours?

The after-hours collapse to about **€0.009** followed extreme repricing, heavy volume and likely corporate or market-driven events. Weak fundamentals, historic EPS **-221.36** and low liquidity amplified the move. Check official filings for precise corporate causes.

What are the main financial risks for ALNEV.PA stock holders?

Key risks include persistent negative earnings, cash flow shortfalls, possible dilution from financing, and clinical-stage biotech risk. Current ratio **0.65** and distorted enterprise value indicate balance-sheet and liquidity vulnerability.

Does Meyka AI expect ALNEV.PA stock to recover?

Meyka AI's forecast model projects **€0.02** within 12 months versus current **€0.0085**, implying **135.29%** upside, but this is model-based and not guaranteed. Recovery depends on financing, restructuring or clinical progress.

Should retail investors buy ALNEV.PA stock now?

Given the steep fall, low market cap and mixed analyst signals, ALNEV.PA is speculative and risky. Use small position sizes, a defined exit, and monitor company announcements and liquidity before adding exposure.

EU Stocks

ALNEV.PA Neovacs (EURONEXT) €0.009 after-hours 12 Jan 2026: watch catalysts

ByDanny Kontos January 12, 2026January 12, 2026

ALNEV.PA stock plunged in after-hours trade on 12 Jan 2026 to about €0.009, following a collapse from a previous close near €1.80 earlier in the period. The move left volume at 1,687,824 shares and a market cap around €3,908.00, signalling a near-total repricing of Neovacs S.A. on EURONEXT (Europe). We examine the drivers behind this top loser, link financial ratios to the price action, and outline short-term signals traders should watch.